Garrett Aikens and Spencer Durham discuss the recent Alabama Department of Public Health (ADPH) Alabama Emergency Response Technology (ALERT) that was sent out on January 21, 2025 regarding an ongoing investigation into reports of potential adverse events in Alabama after injection of ceftriaxone (Rocephin®), a 3rd generation cephalosporin commonly used in both the inpatient and outpatient settings.
For CE credit, please review the following information below and visit this link to claim your credit:
Target
Audience: Pharmacists and Pharmacy Technicians
CEU: 0.5 contact hours (.05 CEU) of CPE credit
ACPE UAN: 0178-0000-25-103-H01-P/T
Activity Type: Knowledge-based
Initial Release Date: January 28, 2025
Expiration Date: January 28, 2027
Learning Objectives
Describe the nature of the reported adverse events potentially associated with ceftriaxone injection.
Discuss the prevalence of allergic reactions to cephalosporins including ceftriaxone.
Submit an observed potential adverse drug event to the ADPH and FDA MedWatch.
Alabama Pharmacy Association Research & Education Foundation is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
Resources:
ADPH ALERT Ceftriaxone Potential Adverse Events, dated January 21, 2025
ADPH ALERT: Ceftriaxone Potential Adverse Events (update), dated January 24, 2025
ADPH Adverse Drug Event Reporting
FDA MedWatch Adverse Drug Event Reporting
Related Continuing Education:
February 11: The Efficacy, Safety, and Overuse of Ceftriaxone: An Antimicrobial Stewardship Discussion (Virtual)
February 13: ENCORE: The Efficacy, Safety, and Overuse of Ceftriaxone: An Antimicrobial Stewardship Discussion (Virtual)
February 14-16, 2025: Alabama Pharmacy Association Mid-Winter Conference (Opelika, AL)
